

## State of Oklahoma Oklahoma Health Care Authority Besponsa® (Inotuzumab Ozogamicin) Prior Authorization

	Member Name:	Date of Birth:	Member ID#:
Billing Provider Information		Drug Information	1
SoonerCare Provider ID:			
Prescriber NPI:		Billing Provider Inform	nation
Prescriber NPI:	SoonerCare Provider ID:	Provider Name:	
Prescriber Name: Prescriber Fax:  Specialty:  Criteria  For Initial Authorization (Initial approval will be for the duration of 6 months):  1. Will inotuzumab ozogamicin be used as a single-agent? Yes No  2. Please indicate the diagnosis and information:  Acute Lymphoblastic Leukemia (ALL)  A. What is the Philadelphia chromosome status of the leukemia?  Philadelphia chromosome negative (Ph-) ALL  Philadelphia chromosome positive (Ph+) ALL  Nhown  B. Does the patient have relapsed or refractory disease? Yes No  C. Is member intolerant/refractory to two or more Tyrosine Kinase Inhibitors (TKIs)?  Yes No  If answer is none of the above, please indicate diagnosis:  Additional Information:  For Continued Authorization:  1. Date of last dose:  2. Does member have any evidence of progressive disease while on inotuzumab ozogamicin?  Yes No  3. Has the member experienced adverse drug reactions related to inotuzumab ozogamicin therapy?  Yes No  Yes No  Additional Information:  Additional Information:	Provider Phone:	Provider Fax:	
Prescriber Phone:		Prescriber Informat	tion
Criteria  For Initial Authorization (Initial approval will be for the duration of 6 months):  1. Will inotuzumab ozogamicin be used as a single-agent? Yes No 2. Please indicate the diagnosis and information:    Acute Lymphoblastic Leukemia (ALL)   A. What is the Philadelphia chromosome status of the leukemia?   Philadelphia chromosome negative (Ph-) ALL   Philadelphia chromosome positive (Ph+) ALL   Unknown   B. Does the patient have relapsed or refractory disease? Yes No   C. Is member intolerant/refractory to two or more Tyrosine Kinase Inhibitors (TKIs)?   Yes No   If answer is none of the above, please indicate diagnosis: Additional Information:  For Continued Authorization:  1. Date of last dose:   2. Does member have any evidence of progressive disease while on inotuzumab ozogamicin?   Yes No   3. Has the member experienced adverse drug reactions related to inotuzumab ozogamicin therapy?   Yes No   If yes, please specify adverse reactions: Additional Information:	Prescriber NPI:	Prescriber Name:	
For Initial Authorization (Initial approval will be for the duration of 6 months):  1. Will inotuzumab ozogamicin be used as a single-agent? Yes No 2. Please indicate the diagnosis and information:    Acute Lymphoblastic Leukemia (ALL)   A. What is the Philadelphia chromosome status of the leukemia?   Philadelphia chromosome negative (Ph-) ALL   Philadelphia chromosome positive (Ph+) ALL   Unknown   B. Does the patient have relapsed or refractory disease? Yes No   C. Is member intolerant/refractory to two or more Tyrosine Kinase Inhibitors (TKIs)?   Yes No   If answer is none of the above, please indicate diagnosis: Additional Information:    For Continued Authorization:   1. Date of last dose: 2. Does member have any evidence of progressive disease while on inotuzumab ozogamicin?   Yes No 3. Has the member experienced adverse drug reactions related to inotuzumab ozogamicin therapy?   Yes No If yes, please specify adverse reactions: Additional Information:	Prescriber Phone:	Prescriber Fax:	Specialty:
1. Will inotuzumab ozogamicin be used as a single-agent? Yes No 2. Please indicate the diagnosis and information:    Acute Lymphoblastic Leukemia (ALL)   A. What is the Philadelphia chromosome status of the leukemia?   Philadelphia chromosome negative (Ph-) ALL   Philadelphia chromosome positive (Ph+) ALL   Unknown   B. Does the patient have relapsed or refractory disease? Yes No   C. Is member intolerant/refractory to two or more Tyrosine Kinase Inhibitors (TKIs)?   Yes No   If answer is none of the above, please indicate diagnosis: Additional Information:    For Continued Authorization:   Date of last dose: No   See No No_		Criteria	
<ol> <li>Date of last dose:</li></ol>	A. What is the Ph  Philace Philace Dhilace Unknown B. Does the patie C. Is member into	iladelphia chromosome status of the delphia chromosome negative (Ph-)delphia chromosome positive (Ph+)own nt have relapsed or refractory diseablerant/refractory to two or more Type No	) ALL ) ALL ase? Yes No rosine Kinase Inhibitors (TKIs)?
	Does member have any evid Yes No      Has the member experience Yes No  If yes, please specify adverse real Additional Information:	ed adverse drug reactions related to	o inotuzumab ozogamicin therapy?

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

will result in processing delays.

University of Oklahoma College of Pharmacy Pharmacy Management Consultants Product Based Prior Authorization Unit

> Fax: 1-800-224-4014 Phone: 1-800-522-0114 Option 4

## **CONFIDENTIALITY NOTICE**

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.